Rankings / Weight Loss — Incretins & Amylin
Mazdutide (IBI362)
Weight loss · GLP-1/glucagon agonist (dual)
Tier B+
What this is
Innovent Biologics; Chinese-approved for obesity and T2D in 2025. GLORY-1 Phase 3 (China, n>600) showed -16.8% body weight at 32 weeks at 9 mg dose. Meaningful for biohacker readers because it reaches similar magnitude to tirzepatide and is already prescribed in China while Western markets wait. Particular interest for MASLD/NAFLD due to hepatic glucagon effects.
Mechanism
Dual GLP-1 and glucagon receptor agonist; glucagon arm increases hepatic fat oxidation and energy expenditure (similar mechanism to survodutide); developed by Innovent (China) under license from Lilly's OXM3
Dose & route
4-9 mg SC weekly
Citations
- https://doi.org/10.1016/j.metop.2026.100463
- https://pubmed.ncbi.nlm.nih.gov/40421736/
- https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01184-1/fulltext
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.